Rating Change
Leerink Partners analysts initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a rating of Outperform on October 12, 2026.
new coverageNASDAQ:NKTR
Leerink Partners Initiates Coverage on Nektar Therapeutics (NKTR) with Outperform
Leerink Partners analysts initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a rating of Outperform on October 12, 2026.
At publication ·
What changed
Nektar Therapeutics (NASDAQ:NKTR) · new coverage
- Firm
- Leerink Partners
- Rating
- Outperform
- Price at event
- $39.84
- Market capitalization
- $1.0B
At a glance
Key takeaways
- Leerink Partners initiated Outperform coverage on Nektar Therapeutics (NKTR) on October 12, 2026, as the stock trades at $39.84 with a $1.0B market cap.
Market Context
Nektar Therapeutics operates in the Healthcare sector. The stock currently trades at $39.84 with a market capitalization of $1.0B.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Nektar Therapeutics.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Nektar Therapeutics
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Neutral | N/A |
| Oct 12, 2026 | Leerink Partners | Outperform | N/A |
| Oct 09, 2026 | BTIG | Buy | N/A |
| Oct 09, 2026 | Raymond James | Market Perform | N/A |
| Oct 02, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NKTR Stock Page
Frequently Asked Questions
What does the Outperform rating mean for NKTR?
A rating of Outperform from Leerink Partners reflects the analyst's outlook on Nektar Therapeutics (NASDAQ:NKTR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NKTR forecast page.